Stopped: NIA funded the first phase of the R21. The clinical trial never began as the R33 was not supported.
Polypharmacy is common among older adults in the United States and is associated with harms such as adverse drug reactions and higher costs of care. This pilot-phase project is designed to test two electronic health record (EHR)-based behavioral economic nudges to help primary care clinicians reduce the rate of high-risk polypharmacy among their older adult patients.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
High-risk polypharmacy criterion: Fall condition-drug interaction
Timeframe: 28 months
High-risk polypharmacy criterion: Fall drug-drug interaction
Timeframe: 28 month
High-risk polypharmacy criterion: CKD-glyburide/glimepiride interaction
Timeframe: 28 months
High-risk polypharmacy criterion: CKD-NSAID interaction
Timeframe: 28 months
High-risk polypharmacy criterion: CHF-NSAID interaction
Timeframe: 28 months
High-risk polypharmacy criterion: CHF-non-dihydropyridine calcium channel blocker interaction
Timeframe: 28 months
High-risk polypharmacy criterion: CHF-thiazolidinedione interaction
Timeframe: 28 months